US FDA approved Krintafel (tafenoquine) for the radical cure of P.vivax in malaria

GSK and Medicines for Malaria Venture (MMV) today announced that the United States Food and Drug Administration (FDA) has approved, under Priority Review, single-dose Krintafel(tafenoquine) for the radical cure (prevention of relapse) of Plasmodium vivax (P. vivax) malaria in patients aged 16 years and older who are receiving appropriate antimalarial therapy for acute P. vivax infection. Read more on their official website: https://www.gsk.com/en-gb/media/press-releases/us-fda-approves-krintafel-tafenoquine-for-the-radical-cure-of-p-vivax-malaria/

Lab statistics

image for Assays completed
Assays completed

2700

this month

image for Problems solved
Problems solved

79

this year

image for Hours in the lab
Hours in the lab

67500

so far this year

image for Visitors Greeted
Visitors Greeted

212

in the last month

EXPLORE WHAT WE CAN DO AT MOLOGIC

Take a look at our expertise. And if you can't see exactly what you're after, contact us. We'll be delighted to discuss your project with you.

Contact us